With a quickly growing range of therapeutic options precise prognostic stratification became particularly important for clinical decision making in patients with pulmonary arterial hypertension (PAH). Assessment of disease-specific functional class remains the simplest method and is a fairly reliable way of assessing severity of PAH, and current guidelines recommend a therapeutic algorithm based on functional class evaluation. Six-minute walk is the most widely used test assessing exercise tolerance both in clinical practice and in clinical trials testing new therapies in PAH. Right heart catheterization with a vasoreactivity test is mandatory to identify a subgroup that has good long-term prognosis when treated with calcium channel blockers alone. Echocardiographic variables of documented prognostic value in PAH are not those directly correlated with pulmonary arterial pressure (PAP). Instead, the presence of pericardial effusion, enlarged right atrium, and elevated Doppler index of right ventricular performance have been the most consistently reported signs of poor prognosis. Low or decreasing brain natriuretic peptide (BNP) suggests a good outcome whereas troponin T leak persisting despite therapy is a poor prognostic sign. Biomarkers seem particularly useful for noninvasive follow-up of patients with PAH, and due to simplicity and low costs may successfully compete with echocardiography.
The reasons for evaluating patients presenting with pulmonary arterial hypertension (PAH) are twofold: to assist in initial therapeutic triage and to perform a kind of snapshot that will help in objective follow-up of disease progression and effects of treatment. A patient in whom PAH has been diagnosed, by definition has either no clearly identifiable cause (with or without familial history) or has one of the following associated conditions: connective tissue disease (CTD), human immunodeficiency virus (HIV) infection, portal hypertension, congenital heart disease (CHD) with corrected or uncorrected shunt, pulmonary veno-occlusive disease (PVOD), or pulmonary capillary hemangiomatosis (PCH). Belonging to an individual class of PAH already conveys an important message regarding the expected natural course of the disease and also, to some extent, the response to treatment. Existing data seem to suggest a prognostic gradient-from worse to mildest-starting with PVOD and PCH closely followed by CTD, with portopulmonary hypertension and especially PAH associated with CHD on another side of the prognostic scale ( Fig. 1 ). Idiopathic and familial PAH seem to have an intermediate prognosis, superior to that of HIV-associated PAH but worse compared with anorectic druginduced PAH. 1, 2 Further evaluation of a patient presenting with PAH requires assessment of prognostic markers, preferably those that have been found to maintain their prognostic power when rechecked during follow-up. Alternatively, surrogate end points could be identified and used as a threshold for treatment escalation or-it is hoped-withdrawal. Many prognostic markers and surrogate end points were reported as useful in idiopathic PAH, 3 previously referred to as primary pulmonary hypertension (PPH). Little is known about their performance in other categories of PAH as well as their cost-effectiveness and the relative precision with which they predict the patient's outcome. According to recent therapeutic algorithms a minimalist approach would be to assess pulmonary vascular reactivity and functional class. 4, 5 However, new challenges, including decisions whether to start with oral or parenteral treatments with their inherent risks and complexity, whether and when to move to the unexplored territory of combination therapy, and when to risk aggressive interventions like atrial septostomy or lung transplantation, all require more precise dynamic positioning of a patient on a prognostic scale.
This article: assessed and taken into consideration (Table 1) . 5 Assessment of FC conveys information that combines data regarding exercise tolerance and quality of life. Although it is somewhat subjective, FC was found to be strongly related to survival in the 194 conventionally treated patients diagnosed with PPH in the early 1980s and entered into the National Institutes of Health (NIH) registry. The median survival time of patients in class IV, III, and I-II was 6 months, 2.5 years, and 6 years, respectively. 6 Recently, in two large (n ¼ 162 and 178) retrospective trials baseline FC was found of prognostic importance in class III-IV idiopathic pulmonary arterial hypertension (IPAH) patients subsequently treated with intravenous (IV) epoprostenol. In both trials patients initially in FC III had significantly higher survival rates at 3 and 5 years follow-up. 7, 8 Even more importantly, FC reassessed after 3 months of IV epoprostenol therapy predicted subsequent survival. Indeed, patients remaining in FC III or IV showed unacceptably high mortality at 3 and 5 years, warranting early listing for lung transplantation. In summary FC in IPAH patients, regardless of whether they were on conventional treatment, prior to or after 3 months of IV epoprostenol provides important insight into long-term outcome.
It seems fair to extrapolate those data and suggest that the persistence of FC III or IV despite 3 months of therapy should be considered justification for treatment escalation either by dose increase, switching from oral to parenteral administration, adding another class of drug, or an intervention such as atrial septostomy or listing for lung transplantation. 5 The 6-minute walk test (6MWT) is the most widely used test assessing exercise tolerance in patients with PAH both in clinical practice and as an end point in most clinical trials. Although one could expect stronger correlations of this continuous variable and survival, in fact the distance covered during 6 minutes seems to provide similar prognostic information to that derived from FC. Most of the trials looking at prognostic significance of the 6MWT were affected by nonhomogeneous treatment applied either at baseline or during the follow-up phase. Nevertheless, a shorter 6MWT distance was related to worse outcome. In a trial in which 73 out of 81 patients on chronic IV epoprostenol could be evaluated $ 1 year after initiation of therapy, baseline 6MWT distance < 153 m predicted worse survival. 9 Reported median values separating patients with PAH and better or worse outcome were 250 m and 332 m at baseline and 380 after 3 months of IV epoprostenol treatment. 7, 10 Unfortunately receiver-operating curves (ROC) were not used to provide a more universal criterion of adverse outcome based on the distance covered in the 6MWT. In one trial the distance covered during the 6MWT 3 months after initiation of IV epoprostenol, but not the change in 6MWT when compared with baseline, was found of prognostic significance. 7 The 6MWT was among three variables independently related to survival identified in a trial that followed a mixed group of patients with severe precapillary pulmonary hypertension (PH). This trial analyzed outcome of 51 patients with different categories of PAH and also included five patients with distal chronic thromboembolic disease, thus supporting the prognostic role of the 6MWT in severe PH also outside IPAH.
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Recent data confirmed existence of a ''ceiling effect'' of the 6MWT. It explains better treatment effect observed as an increase in the 6MWT in more severely compromised patients and lack of the effect in patients with a baseline distance above 450 m. 12 During an encouraged 6MWT the patient's motivation could affect the final result. Adding evaluation of dyspnea at the end of the test (e.g., with the Borg dyspnea score or monitoring pulse oximetry during the 6MWT) might help to better interpret its result in individual patients. Indeed, preliminary data show that arterial oxygen saturation > 10% during the 6MWT increased mortality risk 2.9 times over a median follow-up of 26 months. 13 Other measures of exercise tolerance, including the shuttle test and time tolerated during treadmill exercise, gained less clinical popularity as tools for initial assessment, though, if subsequently repeated, these can also be considered useful for monitoring progression of PAH or effects of therapy. Cardiopulmonary exercise test (CPET) with measurement of peak oxygen consumption (VO 2 max) has not been incorporated into routine clinical practice to assess patients with PAH. Although theoretically of great interest it is limited by 18 to 37% dropout of patients who cannot complete the test. 10, 14 Nevertheless, in the largest study, in which 70 out of 86 patients could be evaluated, VO 2 max < 10.4 mL/kg/min estimated based on the ROC curve was found to be one of the two strongest independent predictors of worse survival, together with peak systolic blood pressure < 120 mm Hg. Using variables that can be derived from CPET but do not require maximal exercise test such as anaerobic threshold is promising but still experimental.
HEMODYNAMICS AND VASOREACTIVITY TESTS
Right heart catheterization is always required for definitive confirmation of PAH.
Also, vasoreactivity test is considered mandatory in patients with PAH because it can identify a subgroup that has a good long-term prognosis when treated with calcium channel blockers (CCBs).
For these reasons right heart hemodynamics should be available for analysis in every newly diagnosed PAH patient. Because progressive increase in RV afterload due to pulmonary vascular obliteration constitutes the basic physiophathological abnormality of PAH, not unexpectedly hemodynamic variables were found to be related to prognosis. This was especially evident in the early series of patients on conventional therapy. In the largest study so far, resulting from the NIH registry, cardiac index (CI), mean right atrial pressure (mRAP), and mean pulmonary arterial pressure (mPAP) were the strongest predictors of survival in univariate analysis. Those three variables were also the only independent predictors of survival in multivariate analysis. Where P(%) is the probability of survival in assumed time (t), PAP is the mean pulmonary artery pressure (mm Hg), RAP is the mean right atrial pressure (mm Hg), and CI is the cardiac index (l/min Â m 2 ). The ''D'Alonzo equation'' developed for calculation of expected survival based on CI, mRAP, and mPAP, and thereafter externally verified in a conventionally treated Mexican cohort of 61 patients with IPAH, can still be used for approximate assessment of baseline hemodynamic severity in patients with PAH. 15 However, it should be remembered that the calculated expected survival would not apply to patients receiving pharmacotherapy according to current standards. Applicability of the D'Alonzo equation to patients other than those with IPAH is unknown. Recently McLaughlin et al summarized the data from six trials that assessed the relationship of directly measured baseline hemodynamics to survival in IPAH and found mRAP to be the most powerful prognostic marker in patients treated either conventionally or with IV epoprostenol. 1 However, lower baseline CI and mixed venous oxygen saturation (MVO 2 ) had documented prognostic value only in conventionally treated patients. This by no means decreases the obvious value of reassessing CI in patients with PAH receiving chronic contemporary therapy. In fact CI emerges as one of the key parameters assisting in therapeutic decisions. Assessment of CI is the principal reason for repeated right heart catheterizations (RHC) performed on a routine basis at 1-to 2-year intervals at some of the leading tertiary PAH referral centers (Gerald Simonneau, Valerie McLaughlin, personal communication). Interestingly, mPAP was reported to have paradoxical relation to survival in IPAH patients treated with IV epoprostenol. Less than the median mPAP values at baseline and after 3 months of treatment were related to worse prognosis in patients initially in class III and IV. 7 Although this was considered by the authors as a potential statistical artifact, it may in fact point at a subgroup with inadequate right ventricular systolic function and afterload compensation.
In a small fraction of IPAH patients (5-15%) pulmonary arteries retain the ability to dilate such that they effect a significant reduction of right ventricular afterload. 16 This can be verified by acute administration of a potent vasodilating agent (e.g., prostacycline, adenosine, or nitric oxide) during right heart catheterization. 5 Most of the acutely responding patients (''responders'') seem to benefit from chronic oral treatment with CCBs. Responders treated with CCBs have an excellent prognosis when compared with nonresponders on conventional therapy. 15, 17 Though it is unclear to what extent the good outcome of responders is due to CCB treatment and to what extent the different type and dynamics of vascular changes to their identification is mandatory for initial treatment triage. Although it seems that most responders represent IPAH patients, the current guidelines suggest vasodilator testing in all categories of PAH regardless of associated conditions or FC. 5 Until recently a fall of > 20% of both mPAP and pulmonary vascular resistance warranted consideration for CCB therapy. Unfortunately many of those patients failed to demonstrate significant long-term benefit with this therapy. Therefore, recently more stringent criteria were suggested. A positive response is currently defined as a reduction of mean PAP ! 10 mm Hg to reach an absolute value of mean PAP 40 mm Hg with an increase or unchanged cardiac output. 18 Although several agents seem similarly useful to identify responders among IPAH patients, nitric oxide inhalations with a very short half-life and single-dose strategy gained the greatest popularity (Table 2) . Although vasodilator testing showing vascular responsiveness indicates a good prognosis, the longterm effects of CCBs should be monitored because they can decrease or disappear with time, prompting escalation of treatment. 5 
ECHOCARDIOGRAPHY
Echocardiography is a well-established screening test for pulmonary hypertension and provides a relatively reliable means of noninvasive estimation of systolic and diastolic PAP. Interestingly, echocardiographic variables of documented prognostic value in PAH are not those directly correlated to PAP. In addition pharmacological treatment of PPH usually results in only minor changes in systolic PAP, too small to be reliably followed in individual patients by Doppler echocardiography. Indeed, it was the presence and semiquantitatively assessed volume of pericardial effusion on echocardiography that was most consistently reported to relate to prognosis in patients with IPAH 9, 19, 20 (Fig. 2) . Leftward shifting of the interventricular septum and, more recently, right atrial area above the median were also reported to independently increase the risk of death or transplantation among 81 PPH patients followed up for a mean of 36.9 AE 15.4 months. Rather than the level of PAP those signs seem related to the chronically increased right heart filling pressures, indicating RV failure. Following this line, the Doppler index of global RV dysfunction was suggested by Tei et al 21 as a prognostic index in IPAH patients. It is calculated by subtracting RV ejection time (RVET) from total RV systolic time (the latter measured as the interval between cessation and reappearance of tricuspid diastolic flow). It is thus possible to assess the combined duration of systolic and diastolic isovolumetric time intervals of RV isovolumetric contraction time (ICT) and isovolumetric relaxation time (IRT), respectively. In a retrospective study involving 53 PPH patients this index of myocardial dysfunction, calculated as (ICT þ IRT)/RVET, was independent from heart rate, RV pressure, dilation, or tricuspid regurgitation but correlated with survival. 22 Two-dimensional echocardiography provides reliable information about the diameter of the pulmonary trunk. A large pulmonary artery aneurysm at initial assessment or especially its quick further expansion at follow-up may suggest impending rupture and sudden death. Listing for urgent lung transplantation, even despite satisfactory hemodynamic and functional indices, should be considered in such cases. 23 Echocardiographic indices related to RV systolic and left ventricular diastolic function were found useful to compare average effects of treatment between the study subgroups receiving either active drug or placebo. 24 Right ventricular size, left ventricular eccentricity index, and diastolic filling pattern all seem related to functional improvement observed with active pharmacological treatment of PAH, but proof of their prognostic significance is lacking. Moreover, relatively poor reproducibility of echocardiography requires timeconsuming measurements of many variables to reliably understand the direction and magnitude of changes in an individual patient. 
BIOMARKERS
There is a quickly growing body of evidence supporting the prognostic importance of biomarkers in PAH.
Although there are changes in the levels of many plasma components in patients with PH only few of them seem useful for clinical purposes. Assessment of plasma levels of uric acid (UA) is the most widely available and inexpensive test providing prognostic information. Excess of UA is probably resulting from aborted oxidative metabolism of ischemic peripheral tissues. Its baseline values were found to correlate with survival, whereas its changes were related to changes in pulmonary resistance. Unfortunately UA has been found to increase in renal insufficiency as well as during diuretic treatment. Moreover, many patients with PH and elevated UA are treated with allopurinol, despite the lack of the clinical syndrome of gout. This of course affects correlations of UA levels with outcome. 25 Brain natriuretic peptide (BNP) or its cleaved, inactive twin (N-terminal) NT-proBNP seems to fulfill most of the criteria of a useful biomarker. Similarly to FC and the 6MWT, both baseline BNP values and those taken after 3 months of treatment (mostly with IV or oral prostacycline) were related to prognosis. 26 In general it seems that patients in whom BNP continued to increase despite treatment have worse survival. NTproBNP has an advantage over BNP of longer halftime (2 h vs 20 min), which makes it more stable. Indeed, we found no major changes in NT-proBNP assessed three to four times over a 24-hour period in PAH patients. On the other hand, NT-proBNP is more affected by renal insufficiency, but because the latter is usually due to low cardiac output this may even increase the prognostic value of NT-proBNP.
Because BNP is released as a result of myocardial stretch it is more closely related to right heart conditions than to pulmonary vascular changes. Nevertheless, it is probably currently the best and most universal biomarker that could be used for prognostic evaluation and monitoring in PH.
Troponin T (TnT) detected in plasma is a signal of ongoing destruction of cardiomyocytes' contractile proteins. TnT leakage assessed with a high-sensitivity test allowing for its detection at 0.01 ng/L was found useful in separating subgroups with good and bad outcome among those with severe precapillary pulmonary hypertension (51 with PAH and five with CTEPH [chronic thromboembolic pulmonary hypertension]). Interestingly, in some of those patients introduction of treatment resulted in temporary or permanent elimination of TnT from plasma and seemed to be related to improved outcome. In multivariate analysis the best model predicting survival included TnT, pulmonary vascular resistance, and 6MWT result.
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SUMMARY
Although many potential markers of prognosis exist in patients with PAH, only few have been adequately verified. The main flaws of the published trials are due to nonstandardized treatment regimens following baseline assessment. Also, with few exceptions, median values for the studied group were used to separate between patients with better and worse outcome.
ROC analyses are needed to suggest more universal cutoff values identifying good or bad outcome.
Despite all these problems several signs can be considered as helpful in prognostic evaluation of a newly diagnosed patient with PAH. At least some of them retain their prognostic significance during subsequent therapy. This is helpful to identify patients who remain clinically stable or become unstable, thus warranting escalation of treatment. Although not based on evidence, it seems, that with each new adverse prognostic sign the patient becomes more unstable (Table 3) . Low cardiac output and class III or IV after 3 months of treatment are probably of greatest prognostic impact. As for biomarkers, low or decreasing BNP suggests a good prognosis whereas TnT leak persisting despite therapy is a poor prognostic sign. Biomarkers seem particularly useful for noninvasive follow-up of patients with PAH, and due to simplicity and low costs, they may successfully compete with echocardiography. 
